$ News

Why Analysts See Mersana’s Story Shifting To Deal And CVR Outcomes After $1B Buyout

How Mersana’s Acquisition Is Changing the Story and Analyst Outlook for Investors

How Recent Developments Are Shaping the Day One Biopharma Investment Story

How the Acquisition Is Reshaping Mersana Therapeutics’ Story and Analyst Outlook

Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial Results

Mersana Therapeutics Catapults 200% On Day One Bio's Surprise Buyout

Mersana Therapeutics, Inc. (MRSN) M&A Call Transcript

Day One Biopharmaceuticals: Mersana Acquisition Ignites March Towards Unmet Need

Day One snaps up ADC maker Mersana in backloaded buyout deal

Day One Biopharmaceuticals to Acquire Mersana Therapeutics in Deal Worth Up to $285 Million

Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases

Day One Biopharmaceuticals to Acquire Mersana Therapeutics

Mersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025

Curis (CRIS) Reports Q3 Loss, Beats Revenue Estimates

Wall Street Analysts See a 314.81% Upside in Mersana Therapeutics (MRSN): Can the Stock Really Move This High?

Wall Street Analysts Think Mersana Therapeutics (MRSN) Could Surge 248.83%: Read This Before Placing a Bet

Mersana Therapeutics Second Quarter 2025 Earnings: Misses Expectations

Mersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call Transcript

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results